INBIOGEN CO.,Ltd Logo

INBIOGEN CO.,Ltd

Data mining, bioinformatics, and virtual assistance for the life sciences industry.

101140 | KO

Overview

Corporate Details

ISIN(s):
KR7101140002
LEI:
Country:
South Korea
Address:
서울특별시 강남구 언주로135길 21 2층(논현동), 강남구
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Inbiogen is a life sciences company focused on providing virtual assistance and data mining services to the biotechnology and pharmaceutical industries. The company leverages a team of scientists and bioinformatics specialists to offer a range of services, including bioinformatics analysis, protein modeling, custom database development, and virtual research assistance. It aims to help international biotech companies and research organizations address challenges by extracting valuable knowledge from large datasets. In addition to its core scientific services, Inbiogen also provides marketing assistance and web design and development tailored to the life sciences sector, focusing on delivering customized and cost-effective solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 749.8 KB
2025-07-28 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 85.5 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 831.3 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.4 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.0 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 12.4 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 395.1 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 19.5 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 148.6 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 115.1 KB
2025-03-12 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 20.0 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.3 KB
2025-01-22 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 11.6 KB
2025-01-10 00:00
Regulatory News Service
[기재정정]사업보고서 (2022.12)
Korean 442.9 KB
2025-01-10 00:00
Regulatory News Service
[기재정정]사업보고서 (2023.12)
Korean 1.1 MB

Automate Your Workflow. Get a real-time feed of all INBIOGEN CO.,Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for INBIOGEN CO.,Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for INBIOGEN CO.,Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.